| 31.235 0.005 (0.02%) | 02-09 15:58 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 36.5 | 1-year : | 42.63 |
| Resists | First : | 31.25 | Second : | 36.5 |
| Pivot price | 29.9  |
|||
| Supports | First : | 29.95 | Second : | 29.14 |
| MAs | MA(5) : | 30.89 |
MA(20) : | 29.81 |
| MA(100) : | 22.54 |
MA(250) : | 16.21 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 99.1 |
D(3) : | 96.4 |
| RSI | RSI(14): 82.4 | |||
| 52-week | High : | 31.25 | Low : | 3.6 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IMGN ] has closed below upper band by 8.8%. Bollinger Bands are 30.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 31.27 - 31.39 | 31.39 - 31.5 |
| Low: | 30.88 - 31.04 | 31.04 - 31.17 |
| Close: | 30.96 - 31.22 | 31.22 - 31.43 |
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Mon, 12 Feb 2024
AbbVie Completes ImmunoGen Acquisition - Contract Pharma
Mon, 12 Feb 2024
ImmunoGen Finalizes Merger, Amends Operations, and Delists Shares - TipRanks
Fri, 09 Feb 2024
ImmunoGen Set to Merge with AbbVie, Awaiting Final Approval - TipRanks
Fri, 09 Feb 2024
ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock? - Yahoo Finance
Fri, 09 Feb 2024
Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means (NASDAQ:IMGN) - Seeking Alpha
Tue, 09 Jan 2024
How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 279 (M) |
| Shares Float | 248 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 86.5 (%) |
| Shares Short | 20,610 (K) |
| Shares Short P.Month | 20,640 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.05 |
| Profit Margin | -25.6 % |
| Operating Margin | 22.8 % |
| Return on Assets (ttm) | -8.5 % |
| Return on Equity (ttm) | -19.9 % |
| Qtrly Rev. Growth | 637.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.02 |
| EBITDA (p.s.) | -0.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -198 (M) |
| Levered Free Cash Flow | -133 (M) |
| PE Ratio | -111.54 |
| PEG Ratio | 0 |
| Price to Book value | 15.16 |
| Price to Sales | 30.33 |
| Price to Cash Flow | -44.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|